AIM: To investigate the changing pattern of beta-catenin expression and its prognostic value in advanced colorectal cancer (CRC). METHODS: Archival tumor samples were analyzed for beta-catenin using immunohistochemistry (IHC) in 95 patients with advanced CRC. RESULTS: Membranous beta-catenin expression was found in the normal colorectal epithelium. Almost 100% of CRC cases showed membranous and cytoplasmic expression, and 55 (58%) cases showed nuclear expression. In univariate (Kaplan-Meier) survival analysis, only the nuclear index (NI) was a significant predictor of disease free survival (DFS) (P = 0.023; n = 35), with a NI above the median associated with longer DFS (34.2 mo) than those with a NI below the median (15.5 mo) (P = 0.045, ANOVA). The other indices were not significant predictors of DFS, and none of the three tested indices (for membranous, cytoplasmic, or nuclear expression) predicted disease-specific survival (DSS). However, when dichotomized as positive or negative nuclear expression, the former was a significant predictor of more favorable DFS (P = 0.041) and DSS (P = 0.046). CONCLUSION: Nuclear beta-catenin expression provides additional information in predicting patient outcome in advanced CRC.
AIM: To investigate the changing pattern of beta-catenin expression and its prognostic value in advanced colorectal cancer (CRC). METHODS: Archival tumor samples were analyzed for beta-catenin using immunohistochemistry (IHC) in 95 patients with advanced CRC. RESULTS: Membranous beta-catenin expression was found in the normal colorectal epithelium. Almost 100% of CRC cases showed membranous and cytoplasmic expression, and 55 (58%) cases showed nuclear expression. In univariate (Kaplan-Meier) survival analysis, only the nuclear index (NI) was a significant predictor of disease free survival (DFS) (P = 0.023; n = 35), with a NI above the median associated with longer DFS (34.2 mo) than those with a NI below the median (15.5 mo) (P = 0.045, ANOVA). The other indices were not significant predictors of DFS, and none of the three tested indices (for membranous, cytoplasmic, or nuclear expression) predicted disease-specific survival (DSS). However, when dichotomized as positive or negative nuclear expression, the former was a significant predictor of more favorable DFS (P = 0.041) and DSS (P = 0.046). CONCLUSION: Nuclear beta-catenin expression provides additional information in predicting patient outcome in advanced CRC.
Authors: B Glimelius; R Ristamäki; M Kjaer; P Pfeiffer; T Skovsgaard; K M Tveit; T Linné; J E Frödin; B Boussard; D Oulid-Aïssa; S Pyrhönen Journal: Ann Oncol Date: 2002-12 Impact factor: 32.976
Authors: Daniela E Aust; Jonathan P Terdiman; Robert F Willenbucher; Cornell G Chang; Annette Molinaro-Clark; Gustavo B Baretton; Udo Loehrs; Frederic M Waldman Journal: Cancer Date: 2002-03-01 Impact factor: 6.860
Authors: Sze Chuen Cesar Wong; Elena Siu Fong Lo; King Chung Lee; John K C Chan; W L Wendy Hsiao Journal: Clin Cancer Res Date: 2004-02-15 Impact factor: 12.531
Authors: Stephan E Baldus; Stefan P Mönig; Sandra Huxel; Stephanie Landsberg; Franz-Georg Hanisch; Katja Engelmann; Paul M Schneider; Jürgen Thiele; Arnulf H Hölscher; Hans P Dienes Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: Sebastian Kraus; Christian Vay; Stephan Baldus; Wolfram T Knoefel; Nikolas H Stoecklein; Daniel Vallbohmer Journal: Oncol Lett Date: 2015-05-28 Impact factor: 2.967
Authors: Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Jeffrey A Meyerhardt; Kaori Shima; Katsuhiko Nosho; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Shuji Ogino Journal: JAMA Date: 2011-04-27 Impact factor: 56.272
Authors: Denise G Priolli; Thamy P Canelloi; Camila O Lopes; Júlio C M Valdívia; Natalia P Martinez; Demetrius P Açari; Izilda A Cardinalli; Marcelo L Ribeiro Journal: Int J Colorectal Dis Date: 2013-04-05 Impact factor: 2.571